NCT06747936View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Primary Hypercholesterolemia

Interventions

DRUG

AD-2281

PO, Once daily, 8weeks

DRUG

AD-2282

PO, Once daily, 8weeks

DRUG

Placebo of AD-2282

PO, Once daily, 8weeks

All Listed Sponsors

lead

Addpharma Inc.

INDUSTRY